SARTORIUS STEDIM BIOTECH Stock: New Increase of 2.37% at Close, Continues Its Weekly Rebound
Sartorius Stedim Biotech stock closed this Monday, October 20th at €207.40, up by 2.37% compared to the previous session. This increase is part of a broader movement that has brought the weekly performance to 10.55%, fueled by the revised annual targets announced last Thursday. However, trading volumes remain moderate, with only 0.08% of the capital traded during the session.
Daily and Weekly Performance Highlights
The stock of the biopharmaceutical industry equipment specialist gained €4.80 over the day, thus crossing the €207 threshold. This progress occurs in a generally positive market context, with the CAC 40 showing an increase of 0.39% over the same period. Over a week, the stock significantly outperforms with a jump of 10.55%, while the quarterly performance is at 8.96%. These results contrast with the annual trajectory, which remains slightly negative at -2.12%, whereas the CAC 40 has progressed by 7.79% over twelve months. The limited capital turnover indicates a movement driven more by conviction than by massive speculative positioning.
Strong Growth Momentum from Recent Financial Results
This upward dynamic originates from the publication of the results for the first nine months of the year, unveiled on Thursday, October 16th. The Aubagne-based group recorded a revenue of €2.195 billion during this period, up by 10.2% at constant exchange rates. In the third quarter, revenues reached €706 million, marking an acceleration in growth to 12% on a like-for-like basis, exceeding market expectations. This performance is explained by the strength of the consumables products activities, which generate high margins. Bolstered by these results, Sartorius Stedim Biotech has raised its targets for the full year 2025, now anticipating revenue growth of about 9%, up from 7% previously, with a forecast range of plus or minus two percentage points. The current Ebitda margin is also revised upwards, to about 31% from a range of 30 to 31% previously. The group indicates that these adjustments confirm the continuous recovery of demand in the bioprocess market.
Technical Analysis and Future Outlook
Technically, the stock is now trading above its resistance threshold established at €203.90, a breakthrough that potentially paves the way for a continuation of the upward movement. The stock is positioned well above its 50-day and 200-day moving averages, respectively located at €180.44 and €191.92, confirming the positive underlying trend. The RSI indicator is at 74, approaching the overbought zone without reaching it. The MACD shows a favorable setup with a signal line at 3.62 and a positive histogram at 1.04, indicating bullish momentum. The Bollinger Bands frame the price between €167.93 and €206.77, with the stock now trading close to the upper boundary. The one-month volatility stands at 14.97, reflecting the amplitude of recent movements.
